文献速递贫血与红细胞疾病

羟基脲治疗非洲镰状细胞贫血儿童的生长与青春期发育

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.
PubMed 文献 · Blood Adv · 2026-01-01

REACH 前瞻性试验评估最大耐受剂量羟基脲对撒哈拉以南非洲镰状细胞贫血儿童生长和青春期发育的影响。经过7年治疗,体重、身高和BMI的年龄别z评分均有改善,青春期延迟见于25%–30%的儿童但逐步进展,男性AMH偏低比例较高。长期羟基脲治疗对生长有益且不负面影响青春期发育。

要点

  • 羟基脲治疗改善镰状细胞贫血患儿体重、身高和BMI的年龄别z评分。
  • 25%–30%患儿青春期延迟,但治疗中逐步进展。
  • 男性AMH偏低比例较高(基线52%,随访28%),女性仅4%。

核心结论

  • 长期最大耐受剂量羟基脲治疗与撒哈拉以南非洲镰状细胞贫血儿童体重和身高改善相关。
  • 羟基脲治疗不负面影响青春期发育,尽管部分患儿存在青春期延迟。

研究设计与样本

  • REACH为前瞻性试验,评估最大耐受剂量羟基脲在撒哈拉以南非洲镰状细胞贫血儿童中的可行性、安全性和获益。
  • 纳入1–10岁儿童,开放标签羟基脲治疗并纵向随访7年;女孩296例,男孩310例。
  • 羟基脲起始平均年龄:女孩5.9±2.4岁(范围1.6–10.2),男孩5.4±2.4岁(范围1.3–10.1)。

主要发现

  • 体重年龄别z评分从入组时0.47±0.90改善至治疗中0.69±1.00。
  • 身高年龄别z评分从0.26±0.90改善至0.42±1.00,BMI从0.46±1.00改善至0.85±1.20。
  • 许多参与者IGF-I持续偏低;青春期延迟见于25%–30%儿童,治疗中逐渐进展。
  • 女孩AMH低于第2.5百分位者占4%;男孩基线AMH偏低者占52%,随访时占28%。

临床怎么用

  • 对撒哈拉以南非洲镰状细胞贫血儿童,最大耐受剂量羟基脲长期治疗可改善生长且不损害青春期发育。
  • 治疗期间应监测生长和青春期发育,关注青春期延迟及男性AMH偏低情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with sickle cell anemia (SCA) have poor growth and pubertal development. REACH (Realizing Effectiveness Across Continents with Hydroxyurea) is a prospective trial evaluating the feasibility, safety, and benefits of hydroxyurea at maximum tolerated dose (MTD) for children with SCA in sub-Saharan Africa. Children aged 1 to 10 years received open-label hydroxyurea with longitudinal follow-up. Height, weight, and pubertal staging were collected over 7 years of treatment. Biomarkers included insulin-like growth factor I (IGF-I), IGF-binding protein 3, luteinizing hormone, follicle-stimulating hormone, and anti-Mullerian hormone (AMH). Hydroxyurea commenced at an average (mean ± 1 standard deviation [SD]) age of 5.9 ± 2.4 years (range, 1.6-10.2) for girls (n = 296) and 5.4 ± 2.4 years (range, 1.3-10.1) for boys (n = 310). Using natural history SCA-specific reference curves, the mean weight-for-age z score improved from 0.47 ± 0.90 at enrollment to 0.69 ± 1.00 on hydroxyurea treatment. Height increased from 0.26 ± 0.90 to 0.42 ± 1.00 on treatment, and body mass index from 0.46 ± 1.00 to 0.85 ± 1.20. IGF-I remained low in many participants. Puberty was delayed in 25% to 30% of children, with gradual progress on treatment. AMH was low (<2.5th percentile) in 4% of girls, whereas 52% of boys had low AMH at baseline and 28% at follow-up. Long-term hydroxyurea treatment at MTD is associated with beneficial effects on growth with improved weight and height, and does not negatively affect pubertal developmenty in children with SCA in sub-Saharan Africa. This study was registered at www.clinicaltrials.gov initially as NCT01966731 and is now registered as NCT06171217 for long-term follow-up.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Backeljauw P, Tomlinson G, Smart LR, et al. Growth and puberty in African children with sickle cell anemia treated with hydroxyurea. Blood Adv. 2026. PMID: 41954645. doi:10.1182/bloodadvances.2025019511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。